Cargando…

Intrathecal trastuzumab: immunotherapy improves the prognosis of leptomeningeal metastases in HER-2+ breast cancer patient

We describe the clinical and therapeutic course of a 51-year-old woman with HER-2+ breast cancer who developed leptomeningeal (LM) and spinal cord metastases after 8 years of stable disease on combination therapy with intravenous (IV) trastuzumab. Due to progressive CNS disease, intrathecal (IT) tra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lu, Nu T., Raizer, Jeffrey, Gabor, Erwin P., Liu, Natalie M., Vu, James Q., Slamon, Dennis J., Barstis, John L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4570757/ https://www.ncbi.nlm.nih.gov/pubmed/26380087 http://dx.doi.org/10.1186/s40425-015-0084-y

Ejemplares similares

HER2+ esophageal carcinoma leptomeningeal metastases treated with intrathecal trastuzumab regimen
por: Wu, Scott A, et al.
Publicado: (2023)

Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases
por: Lazaratos, Anna-Maria, et al.
Publicado: (2023)

LPTO-02. INTRATHECAL (IT) TRASTUZUMAB (T) FOR THE TREATMENT OF LEPTOMENINGEAL DISEASE (LM) IN PATIENTS (PTS) WITH HUMAN EPIDERMAL RECEPTOR-2 POSITIVE (HER2+) CANCER: A MULTICENTER PHASE 1/2 STUDY
por: Kumthekar, Priya, et al.
Publicado: (2019)

Intrathecal Trastuzumab Treatment in Patients with Breast Cancer and Leptomeningeal Carcinomatosis
por: Park, Won-Young, et al.
Publicado: (2016)

LPTO-08. INTRATHECAL TRASTUZUMAB PLUS/MINUS IT TOPOTECAN FOR PATIENTS WITH HER2+ BREAST CANCER AND LEPTOMENINGEAL METASTASIS
por: Trevino, Christopher R, et al.
Publicado: (2019)

Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan
por: Alder, Laura, et al.
Publicado: (2023)

Long-term complete response to intrathecal trastuzumab in a patient with leptomeningeal carcinomatosis due to her2- overexpressing breast cancer: Case report
por: García, Francisco José Valdivia, et al.
Publicado: (2020)

Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and/or leptomeningeal disease (ROSET-BM)
por: Niikura, Naoki, et al.
Publicado: (2023)

Immunotherapy in NSCLC Patients With Brain and Leptomeningeal Metastases
por: Pierret, Thomas, et al.
Publicado: (2022)

Intrathecal trastuzumab for leptomeningeal carcinomatosis in patients with human epidermal growth factor receptor 2 positive breast cancer
por: Gulia, Seema, et al.
Publicado: (2016)

Cerebrospinal fluid circulating tumor cells as a quantifiable measurement of leptomeningeal metastases in patients with HER2 positive cancer
por: Malani, Rachna, et al.
Publicado: (2020)

Therapies beyond Physiological Barriers and Drug Resistance: A Pilot Study and Review of the Literature Investigating If Intrathecal Trastuzumab and New Treatment Options Can Improve Oncologic Outcomes in Leptomeningeal Metastases from HER2-Positive Breast Cancer
por: Trifănescu, Oana Gabriela, et al.
Publicado: (2023)

Dose-reduced trastuzumab deruxtecan can be safely used in liver failure and active leptomeningeal metastases
por: Higashiyama, Nicole, et al.
Publicado: (2020)

Breast cancer patients treated with intrathecal therapy for leptomeningeal metastases in a large real-life database
por: Carausu, M., et al.
Publicado: (2021)

Genomic and transcriptomic correlates of immunotherapy response within the tumor microenvironment of leptomeningeal metastases
por: Prakadan, Sanjay M., et al.
Publicado: (2021)

Cyberknife Radiosurgery and Concurrent Intrathecal Chemotherapy for Leptomeningeal Metastases: Case Report of Prolonged Survival of a HER-2+ Breast Cancer Patient Status-Post Craniospinal Irradiation
por: Lekovic, Gregory, et al.
Publicado: (2016)

Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer
por: Canonici, Alexandra, et al.
Publicado: (2013)

Author Correction: Genomic and transcriptomic correlates of immunotherapy response within the tumor microenvironment of leptomeningeal metastases
por: Prakadan, Sanjay M., et al.
Publicado: (2021)

Rapid symptomatic relief of HER2-positive gastric cancer leptomeningeal carcinomatosis with lapatinib, trastuzumab and capecitabine: a case report
por: Jiao, Xiao-Dong, et al.
Publicado: (2018)

Ovarian Adenocarcinoma With Leptomeningeal Metastases
por: Bayas, Angel, et al.
Publicado: (2022)

A Pilot Phase 1 Study of Intrathecal Pemetrexed for Refractory Leptomeningeal Metastases From Non-small-cell Lung Cancer
por: Pan, Zhenyu, et al.
Publicado: (2019)

Heterogeneous distribution of trastuzumab in HER2-positive xenografts and metastases: role of the tumor microenvironment
por: Baker, Jennifer Hazel Elizabeth, et al.
Publicado: (2018)

Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results
por: Glitza Oliva, Isabella C., et al.
Publicado: (2023)

Helical tomotherapy in patients with leptomeningeal metastases
por: Schiopu, Sanziana RI, et al.
Publicado: (2018)

Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies
por: Esteva, Francisco J, et al.
Publicado: (2005)

Potential Biomarkers Associated with Prognosis and Trastuzumab Response in HER2+ Breast Cancer
por: Castro-Guijarro, Ana Carla, et al.
Publicado: (2023)

Trastuzumab-Targeted Biodegradable Nanoparticles for Enhanced Delivery of Dasatinib in HER2+ Metastasic Breast Cancer
por: Niza, Enrique, et al.
Publicado: (2019)

Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2
por: Glitza, Isabella C, et al.
Publicado: (2018)

LPTO-09. INTRATHECAL TOPOTECAN FOR LEPTOMENINGEAL METASTASIS IN SOLID TUMORS: THE MD ANDERSON EXPERIENCE
por: Sinicrope, Kaylyn D, et al.
Publicado: (2019)

Leptomeningeal disease and brain control after postoperative stereotactic radiosurgery with or without immunotherapy for resected brain metastases
por: Minniti, Giuseppe, et al.
Publicado: (2021)

Carcinomatous meningitis: Leptomeningeal metastases in solid tumors
por: Le Rhun, Emilie, et al.
Publicado: (2013)

Leptomeningeal Metastases in Hormone Refractory Prostate Cancer
por: Ng, Jessica Y, et al.
Publicado: (2018)

Anorectal Cancer with Bone Marrow and Leptomeningeal Metastases
por: Zeeneldin, Ahmed, et al.
Publicado: (2018)

How we treat patients with leptomeningeal metastases
por: Le Rhun, Emilie, et al.
Publicado: (2019)

Dural and Leptomeningeal Spine Metastases of Breast Cancer
por: Matos, Fernando, et al.
Publicado: (2019)

Leptomeningeal Metastases: New Opportunities in the Modern Era
por: Wilcox, Jessica A., et al.
Publicado: (2022)

Editorial: Brain and leptomeningeal metastases in lung cancer
por: Vavalà, Tiziana, et al.
Publicado: (2023)

Leptomeningeal Disease (LMD) in Patients with Melanoma Metastases
por: Khaled, Mariam Lotfy, et al.
Publicado: (2023)

How we treat HER2-positive brain metastases
por: Stavrou, E., et al.
Publicado: (2021)

Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma
por: Kawaguchi, Y, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_c313p0i7bv2fnu04ioqnfgaeie